CA2803520C - N-alkoxyamide conjugates as imaging agents - Google Patents

N-alkoxyamide conjugates as imaging agents Download PDF

Info

Publication number
CA2803520C
CA2803520C CA2803520A CA2803520A CA2803520C CA 2803520 C CA2803520 C CA 2803520C CA 2803520 A CA2803520 A CA 2803520A CA 2803520 A CA2803520 A CA 2803520A CA 2803520 C CA2803520 C CA 2803520C
Authority
CA
Canada
Prior art keywords
mmol
pharmaceutically acceptable
alkyl
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2803520A
Other languages
English (en)
French (fr)
Other versions
CA2803520A1 (en
Inventor
Richard R. Cesati
Thomas D. Harris
Simon P. Robinson
Richard J. Looby
Edward H. Cheesman
Padmaja Yalamanchili
David S. Casebier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantheus Medical Imaging Inc
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Publication of CA2803520A1 publication Critical patent/CA2803520A1/en
Application granted granted Critical
Publication of CA2803520C publication Critical patent/CA2803520C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2803520A 2009-07-08 2010-07-08 N-alkoxyamide conjugates as imaging agents Expired - Fee Related CA2803520C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22394609P 2009-07-08 2009-07-08
US61/223,946 2009-07-08
PCT/US2010/001926 WO2011005322A2 (en) 2009-07-08 2010-07-08 N-alkoxyamide conjugates as imaging agents

Publications (2)

Publication Number Publication Date
CA2803520A1 CA2803520A1 (en) 2011-01-13
CA2803520C true CA2803520C (en) 2019-10-22

Family

ID=43429724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2803520A Expired - Fee Related CA2803520C (en) 2009-07-08 2010-07-08 N-alkoxyamide conjugates as imaging agents

Country Status (7)

Country Link
US (2) US8877157B2 (https=)
EP (1) EP2451776B1 (https=)
JP (1) JP5676600B2 (https=)
CN (1) CN102781909B (https=)
AU (1) AU2010271097B2 (https=)
CA (1) CA2803520C (https=)
WO (1) WO2011005322A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI618544B (zh) 2006-12-26 2018-03-21 藍瑟斯醫學影像公司 使心臟神經分布顯像之配位體
US8361438B2 (en) 2008-01-08 2013-01-29 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
CA2803520C (en) 2009-07-08 2019-10-22 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
AU2011253052B2 (en) 2010-05-11 2015-05-14 Lantheus Medical Imaging, Inc. Compositions, methods and systems for the synthesis and use of imaging agents
GB201102189D0 (en) 2011-02-08 2011-03-23 King S College London Materials and methods relating to cardiovascular imaging
EP2753605B1 (en) * 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US20150023873A1 (en) 2011-11-11 2015-01-22 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類MUC1抗體Fab片段
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
CA3115747A1 (en) 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
JPWO2020145228A1 (ja) * 2019-01-07 2021-11-11 アステラス製薬株式会社 配位子及びCEACAM5抗体Fabフラグメントからなる複合体
CN117486698B (zh) * 2023-10-30 2025-08-19 国网安徽省电力有限公司电力科学研究院 烯醇硅醚类化合物制备c-c键偶联产物的方法与sf6的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5122885A (en) 1974-08-13 1976-02-23 Sagami Chem Res Ashiru ll aminosan oo chikanhidorokisamidono seizohoho
JPS5910322B2 (ja) 1975-07-30 1984-03-08 三井東圧化学株式会社 殺草剤
US4859777A (en) 1981-07-01 1989-08-22 Eastman Kodak Company Terpyridine chelating agents
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
EP0247156B1 (en) 1985-11-18 1993-06-23 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
EP0233607B1 (en) 1986-02-18 1991-03-13 E.R. Squibb & Sons, Inc. [(2,2,2-Trichloroethoxy) methoxy]amine
US5064956A (en) 1987-06-24 1991-11-12 The Dow Chemical Company Process for preparing mono-n-alkylated polyazamacrocycles
IT1224627B (it) 1988-04-12 1990-10-04 Guidotti & C Spa Labor Ammidi di acidi ciclometilen_1,2_dicarbossilici adattivita' terapeutica, procedimenti per la loro preparazione e composizioni farmaceutiche che le contengono.
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5089043A (en) 1989-11-09 1992-02-18 Shionogi & Co., Ltd. Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides
JPH0491070A (ja) 1990-08-06 1992-03-24 Kanebo Ltd カリックスアレーン誘導体
US5274129A (en) 1991-06-12 1993-12-28 Idaho Research Foundation, Inc. Hydroxamic acid crown ethers
GB9115375D0 (en) 1991-07-17 1991-09-04 Salutar Inc Compounds
US5639746A (en) 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
TW319763B (https=) 1995-02-01 1997-11-11 Epix Medical Inc
EP0955044B1 (en) 1995-06-26 2005-11-16 Chelator LLC Method of inhibiting bacterial or fungal growth using a complexing agent
DE19914101C1 (de) * 1999-03-22 2000-10-12 Schering Ag Perfluoralkylamide, ihre Herstellung und ihre Verwendung in der Diagnostik
US6461587B1 (en) 1999-03-22 2002-10-08 Schering Aktiengesellschaft Perfluoroalkylamides, their production and their use in diagnosis
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20020002152A1 (en) * 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
EP1377321A4 (en) 2001-02-23 2006-01-11 Bristol Myers Squibb Co RECOVERY ANTAGONISTS RECEIVING DETECTABLE MACROPHAGE RECEPTORS FOR THE IDENTIFICATION OF ATHEROSCLEROSIS AND VULNERABLE PLAQUE BY IMAGING
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
WO2005001415A2 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
WO2005020973A2 (en) 2003-08-29 2005-03-10 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
US20070142417A1 (en) 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
WO2007005491A1 (en) 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
US7618957B2 (en) 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
US8361438B2 (en) 2008-01-08 2013-01-29 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
CA2803520C (en) 2009-07-08 2019-10-22 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents

Also Published As

Publication number Publication date
EP2451776A4 (en) 2015-04-15
WO2011005322A2 (en) 2011-01-13
AU2010271097B2 (en) 2015-12-10
EP2451776A2 (en) 2012-05-16
WO2011005322A3 (en) 2011-04-21
US20120328514A1 (en) 2012-12-27
JP5676600B2 (ja) 2015-02-25
US20150078997A1 (en) 2015-03-19
AU2010271097A1 (en) 2012-03-01
EP2451776B1 (en) 2019-09-18
JP2012532868A (ja) 2012-12-20
HK1178511A1 (en) 2013-09-13
CN102781909A (zh) 2012-11-14
US8877157B2 (en) 2014-11-04
CN102781909B (zh) 2015-06-17
US9393329B2 (en) 2016-07-19
CA2803520A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
CA2803520C (en) N-alkoxyamide conjugates as imaging agents
JP6297561B2 (ja) 造影剤の合成および使用のための組成物、方法およびシステム
JPH05112567A (ja) 6員環を有する巨大環式テトラアザ化合物、その製法及びこれを含有する薬剤
JP6087386B2 (ja) 造影剤としてのn−アルコキシアミド抱合体
HK1171216B (en) N-alkoxyamide conjugates as imaging agents
HK1171216A (en) N-alkoxyamide conjugates as imaging agents
HK1178511B (en) N-alkoxyamide conjugates as imaging agents
HK1148941A (en) N-alkoxyamide conjugates as imaging agents
HK1148941B (en) N-alkoxyamide conjugates as imaging agents
HK1200823B (en) N-alkoxyamide conjugates as imaging agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150708

MKLA Lapsed

Effective date: 20210708